FDA approves updated COVID-19 vaccines for 2026-2027 season

FDA approval COVID-19 vaccine XFG variant mRNA vaccine public health policy

The U.S. Food and Drug Administration (FDA) has approved updated COVID-19 vaccines for the 2026-2027 season, targeting the XFG subvariant of the JN.1 coronavirus lineage. The approved vaccines include mRNA formulations from Moderna and Pfizer-BioNTech, as well as a protein-based option from Novavax-Sanofi.

Eligibility for these updated shots is focused on specific populations: all adults aged 65 and older, and individuals aged 5 to 64 who possess underlying health conditions—such as asthma, diabetes, obesity, or heart disease—that increase the risk of severe illness. Moderna’s Spikevax is authorized for those 6 months and older with underlying conditions, while its mNEXSPIKE formulation is for those aged 12 to 64 with high-risk conditions.

The approvals come amid a shift in federal health policy. Under the Trump administration and Health and Human Services Secretary Robert F. Kennedy Jr., the government has moved away from universal vaccine recommendations toward more restricted, individual-based decision-making. This policy shift, along with recent legal challenges regarding the appointment of vaccine advisory panel members, has raised questions regarding insurance coverage and ease of access for those not meeting the specific high-risk criteria.

Entities

CDC · Centers for Disease Control and Prevention · FDA · Food and Drug Administration · Moderna · Novavax · Pfizer · Pfizer-BioNTech · Robert F. Kennedy Jr.

Claims

What the coverage asserts, and how many sources carry each claim.

[● 3 SOURCES] The approved vaccines are authorized for adults aged 65 and older and for individuals aged 5 to 64 with underlying health conditions that increase the risk of severe illness. www.europesays.com · abc30.com · www.washingtonexaminer.com
[● 2 SOURCES] Moderna’s mNEXSPIKE is approved for individuals aged 12 to 64 with an underlying condition and all adults 65 and older. www.europesays.com · wltreport.com
[○ 1 SOURCE] Pfizer-BioNTech’s mRNA vaccine is approved for adults 65 and older and for individuals aged 5 to 64 with high-risk underlying conditions. www.europesays.com
[● 2 SOURCES] Under the Trump administration and HHS Secretary Robert F. Kennedy Jr., federal COVID-19 vaccine recommendations have shifted toward more restricted eligibility. www.tag24.com · www.deseret.com
[● 2 SOURCES] Moderna’s Spikevax is approved for individuals aged 6 months to 64 years with an underlying condition and all adults 65 and older. americanfaith.com · wltreport.com
[○ 1 SOURCE] Novavax’s protein-based vaccine, Nuvaxovid, is approved for adults 65 and older and for individuals aged 12 to 64 with underlying conditions. www.europesays.com
[● 5 SOURCES] The FDA approved updated COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax-Sanofi for the 2026-2027 season. americanfaith.com · www.europesays.com · www.tag24.com · wltreport.com · www.washingtonexaminer.com
[● 3 SOURCES] The updated vaccines target the XFG subvariant of the JN.1 coronavirus lineage. www.europesays.com · abc30.com · www.deseret.com